Skip to main content
Log in

Very-low dose antacid in treatment of duodenal ulcer

Comparison with cimetidine

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Antacid (AA) in a very low dose (88 mmol/day) was compared to the standard 800-mg dose of cimetidine in healing duodenal ulcers. The influence of sex, age, symptom duration at entry, night pain, smoking, coffee consumption, and alcohol on ulcer healing was studied. The antacid was given in two different schedules: group I-20 ml 1 hr after breakfast and at bedtime; group II-10 ml 1 hr after breakfast and lunch and 20 ml at bedtime. Cimetidine (group III) was given in two divided doses: 400 mg 1 hr after breakfast and 400 mg at bedtime. Endoscopic control was performed after four weeks and, if necessary, after eight weeks of treatment. The healing rate after four weeks of treatment was, respectively, for groups I, II, and III, 45.5%, 55.8%, and 69.4% (group I=group II, and group III different from groups I and II). After eight weeks of treatment the healing rate was 61.5%, 80.8%, and 88.0% for groups I, II, and III, respectively (group II=group III, and group I different from groups II and III). Except for group I, smoking did not influence healing rate. Age, sex, symptoms at entry, night pain, and coffee consumption did not influence the treatment results. The authors concluded that the very low dose of magaldrate (88 mmol/day), when administered in three divided doses (10 ml after breakfast and lunch and 20 ml at bedtime) for eight weeks was as effective as 800 mg of cimetidine (400 mg twice a day) in healing duodenal ulcer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kumar N, Vij JC, Karol A, Anand BS: Controlled therapeutic trial to determine the optimum dose of antacids in duodenal ulcer. Gut 25:1199–1202, 1984

    Google Scholar 

  2. Lam SK, Lam KC, Lai CL, Yeung CK, Yam LYC, Wong WS: Treatment of duodenal ulcer with antacid and sulpiride. A double blind controlled study. Gastroenterology 76:315–322, 1979

    Google Scholar 

  3. Weberg R, Berstad A, Lange O, et al: Duodenal ulcer healing with four antacids tablets daily. Scand J Gastroenterol 20:1041–1045, 1985

    Google Scholar 

  4. Zaterka S, Massuda HK, Eisig JN, Dallaverde Neto E, Miszputen SJ, Leitão OR, Jorge JL, Cordeiro F, Castro LP, Coelho LGV, Castro FJ, Vieira WL: Comparison of low and very low antacid doses in the treatment of duodenal peptic ulcer. Curr Ther Res 47:554–559, 1990

    Google Scholar 

  5. Sakita T: Endoscopic in the diagnosis of early ulcer cancer. Clin Gastroenterol 2:345–360, 1973

    Google Scholar 

  6. Richardson CT, Peterson WL: Clinical pharmacology of antacids.In Antacids in Peptic Ulcer Disease. State of the Art. G Bianchi Porro, CR Richardson (eds). New York, Raven Press, pp 3–16, 1988

    Google Scholar 

  7. Tarnawski A, Hollander D, Cumming D, Krausc WJ, Gergely H, Zipser RD: Are antacids acid neutralizers only? Histologic, ultrastructural and functional changes in normal gastric mucosa induced by antacids. Gastroenterology 86:1276, 1984

    Google Scholar 

  8. Lanz R, Postius S, Szehenyi I, Brune K: PGE2 release from cultured macrophages induced by antacids and sucralfate. Gastroenterology 88:1464, 1985

    Google Scholar 

  9. Preclik G, Stange EF, Gerber K, Fetzer G, Horn H, Ditschuneit H: Stimulation of mucosal prostaglandin synthesis in human stomach and duodenum by antacid treatment. Gut 30:148–151, 1989

    Google Scholar 

  10. Konturek SJ, Brzozowski T, Drozdowicz D, Dembinski A, Navert C: Healing of chronic gastroduodenal ulceration by antacids. Dig Dis Sci 35:1121–1129, 1990

    Google Scholar 

  11. Konturek SJ, Dembinski A, Warsecha Z, Bielanski W, Brzozowski T, Drozdowicz D: Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats. Gut 29:894–902, 1986

    Google Scholar 

  12. Berstad A, Alexander B, Weberg R, Serck-Hanseen A, Holland S, Hirschowitz BI: Antacids reduceCampylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes. Gastroenterology 95:619–624, 1988

    Google Scholar 

  13. Zaterka S, Eisig JN, Arakaki E, Massuda HK, Chinzon D: Gastrite e infecção peloHelicobacter pylori: Influência do magaldrato x placebo. GED 9:140, 1990

    Google Scholar 

  14. Weberg R, Aubert E, Dahlberg O, Dybdahl J, Ellekjara E, Farup PG, Hovdenak N, Lange O, Melsom M, Stallemo O, Vetvik KR, Berstad A: Low-dose antacids or cimetidine for duodenal ulcer? Gastroenterology 95:1465–1469, 1988

    Google Scholar 

  15. Berstad A, Weberg R: Antacids for peptic ulcer: Do we have anything better? Scand J Gastroenterol 21(suppl 125):32–39, 1986

    Google Scholar 

  16. Rydning A, Ragnar W, Lange O, Berstad A: Healing of benign gastric ulcer with low-dose antacids and fiber diet. Gastroenterology 91:56–61, 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zaterka, S., Cordeiro, F., Lyra, L.G.C. et al. Very-low dose antacid in treatment of duodenal ulcer. Digest Dis Sci 36, 1377–1383 (1991). https://doi.org/10.1007/BF01296802

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01296802

Key Words

Navigation